Canaccord Genuity Initiates Coverage On Annovis Bio with Buy Rating, Announces Price Target of $36

Annovis Bio -4.67%

Annovis Bio




Canaccord Genuity analyst Sumant Kulkarni initiates coverage on Annovis Bio (NYSE: ANVS) with a Buy rating and announces Price Target of $36.
Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via